

**SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS  
DOCUMENT BINDER INDEX**

April 20, 2016

**"How Secure are Our Bioresearch Labs? Preventing the Next Safety Lapse"**

| Exhibit Number | Document  |
|----------------|---|
| 1              | NIH General Laboratory Safety Surveys (for third floor in Building 29A)   |
|                | Tab A- 2011 Survey for Room 29A/3C22  |
|                | Tab B- 2011 Survey for Room 29A/3C12  |
|                | Tab C- 2012 Survey for Room 29A/3C22  |
|                | Tab D- 2013 Survey for Room 29A/3C22  |
| 2              | August 22, 2014, Letter From Hon. Dr. Thomas Frieden, Director, CDC; to The Hon. Fred Upton, H. Comm. On Energy & Commerce  |
| 3              | September 18, 2014, Letter From Thomas Kraus, Assoc. Commissioner for Legislation, FDA, to The Hon. Fred Upton, H. Comm. On Energy & Commerce   |
| 4              | September 17, 2014, Letter from Hon. Dr. Francis Collins, Director, NIH, to Hon. Fred Upton, Chairman, H. Comm. On Energy & Commerce  |
| 5              | May 19, 2015, Washington Post Article, "House Panel Seeks Expanded GAO Review of Smallpox Incident at NIH"  |
| 6              | September 2015, CDC, Minutes from the April 23, 2015- CDC Advisory Committee to the Director  |
| 7              | June 4, 2012, Letter from Robbin Weyant, Director, CDC Division of Select Agents and Toxins, to Deborah Wilson, Responsible Official, NIH   |
| 8              | November 2011, NCI Frederick Campus, Biosafety Technical Bulletin: Cold Rooms and Mold  |
| 9              | December 11, 2014, Email from Meghan Scott, FDA, to Majority Staff Committee, Subject: Federal Select Agents- Follow-up Questions   |
| 10             | December 1, 2009, Memorandum from Joseph E. Vengrin, Deputy Inspector for Audit Services, HHS-OIG, to Hon. Francis Collins, Director NIH, Subject: Review of the National Institutes of Health, Bethesda, Maryland Laboratories' Compliance with Select Agent Regulations (A-03-09-00350) |
| 11             | September 8, 2014, Letter from Robbin Weyant, Director, CDC Division of Select Agents and Toxins, to David Blank, Senior Counsel, HHS-OIG, Subject: National Institutes of Health (Registration #C20110919-1265)  |
|                | Tab A- August 8, 2014, Memorandum from CDC, DSAT, to Deborah Wilson, Responsible Official, NIH, RE: Joint CDC and FBI Investigation of Vials labeled "Variola" and other Vials Discovered on the NIH, Bethesda, MD Campus   |
|                | Tab B- Notification of Possession of Select Agents or High Consequence  |

| Exhibit Number | Document  |
|----------------|---|
|                | Livestock Pathogens and Toxins  |
|                | Tab C-NIH Responses to CDC Entity Request for Information   |
|                | Tab D- August 18, 2014, Memorandum from The White House, Subject: Enhancing Biosafety and Biosecurity in the United States  |
| 12             | February 2016, USDA and HHS, Report to Congress: Notifications of Thefts, Losses, or Releases of Select Agents and Toxins   |
| 13             | December 15, 2011, Memorandum from Dr. Gerald M. Feldman, Investigator, FDA to Dr. Marjorie Shapiro, Chief of Molecular and Developmental Immunology  |
| 14             | General Laboratory Safety Surveys, Division of Occupational Health and Safety, ORS  |
| 15             | August 20, 2014, Email from Robbin Weyant, Director, CDC Division of Select Agents and Toxins, to CDC staff, Subject: Report  |
| 16             | NIH, Biosafety Level 2 Safety Survey  |
| 17             | June 5, 2012, NIH, Select Agent Investigative Report, Findings and Actions  |
| 18             | September 25, 1995, Washington Post Article, "NIH Denies It Has Smallpox Sample: Scientist in Charge of Lab Says Allegation Is Categorically False"   |
| 19             | April 1, 2016, Letter from Hon. Fred Upton, Chairman, H. Comm. On Energy & Commerce, to Hon. Thomas Frieden, Director, CDC, CONFIDENTIAL  |
| 20             | December 9, 2011, Letter from Robbin Weyant, Director, CDC Division of Select Agents and Toxins, to Tony Maida, Senior Counsel, DHHS OIG, Subject: Rocky Mountain Laboratories (Registration #C20090508-0835) |